Skip Navigation

Cardiovascular Research 2005 65(3):581-586; doi:10.1016/j.cardiores.2004.08.008
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Levitzki, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levitzki, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

PDGF receptor kinase inhibitors for the treatment of restenosis

Alexander Levitzki*

Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel

* Tel.: +972 2 6585 404; fax: +972 2 6512 958. Email address: levitzki{at}vms.huji.ac.il

The clogging of arteries by neointima is a hallmark of atherosclerosis and of restenosis following balloon angioplasty. The realization in the 1980s that PDGF and its receptor play a key role in the onset of neointimal formation led us to develop PDGFR kinase inhibitors as antirestenosis agents. In this review, we describe the development of these inhibitors and their implementation as antirestenosis agents by localized delivery to the site of injury.

KEYWORDS PDGF; Tyrphostins; Restenosis; Cancer


This review is dedicated to the memory of Prof. Amiram Eldor, a pioneer in prevention of restenosis, who died in a plane crash in 2001.

Time for primary review 22 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. Zhuang, Q. Pu, B. Ceacareanu, Y. Chang, M. Dixit, and A. Hassid
Chronic insulin treatment amplifies PDGF-induced motility in differentiated aortic smooth muscle cells by suppressing the expression and function of PTP1B
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H163 - H173.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Rodriguez, J. Martinez-Gonzalez, B. Raposo, J. F. Alcudia, A. Guadall, and L. Badimon
Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases
Cardiovasc Res, July 1, 2008; 79(1): 7 - 13.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Jin, E. M. Hansson, S. Tikka, F. Lanner, C. Sahlgren, F. Farnebo, M. Baumann, H. Kalimo, and U. Lendahl
Notch Signaling Regulates Platelet-Derived Growth Factor Receptor-{beta} Expression in Vascular Smooth Muscle Cells
Circ. Res., June 20, 2008; 102(12): 1483 - 1491.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
C. E. Chadjichristos, S. Morel, J.-P. Derouette, E. Sutter, I. Roth, A. C. Brisset, M.-L. Bochaton-Piallat, and B. R. Kwak
Targeting Connexin 43 Prevents Platelet-Derived Growth Factor-BB-Induced Phenotypic Change in Porcine Coronary Artery Smooth Muscle Cells
Circ. Res., March 28, 2008; 102(6): 653 - 660.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. C.M. Siow and A. T. Churchman
Adventitial growth factor signalling and vascular remodelling: Potential of perivascular gene transfer from the outside-in
Cardiovasc Res, September 1, 2007; 75(4): 659 - 668.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
K. Nakamura, S.-i. Yamagishi, T. Matsui, T. Yoshida, K. Takenaka, Y. Jinnouchi, Y. Yoshida, S.-i. Ueda, H. Adachi, and T. Imaizumi
Pigment Epithelium-Derived Factor Inhibits Neointimal Hyperplasia after Vascular Injury by Blocking NADPH Oxidase-Mediated Reactive Oxygen Species Generation
Am. J. Pathol., June 1, 2007; 170(6): 2159 - 2170.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
C. M. Mallawaarachchi, P. L. Weissberg, and R. C. M. Siow
Antagonism of platelet-derived growth factor by perivascular gene transfer attenuates adventitial cell migration after vascular injury: new tricks for old dogs?
FASEB J, August 1, 2006; 20(10): 1686 - 1688.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. E. Chadjichristos, C. M. Matter, I. Roth, E. Sutter, G. Pelli, T. F. Luscher, M. Chanson, and B. R. Kwak
Reduced Connexin43 Expression Limits Neointima Formation After Balloon Distension Injury in Hypercholesterolemic Mice
Circulation, June 20, 2006; 113(24): 2835 - 2843.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T. Schachner
Pharmacologic inhibition of vein graft neointimal hyperplasia
J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 1065 - 1072.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Z. Chen, F. Y. Lee, K. N. Bhalla, and J. Wu
Potent Inhibition of Platelet-Derived Growth Factor-Induced Responses in Vascular Smooth Muscle Cells by BMS-354825 (Dasatinib)
Mol. Pharmacol., May 1, 2006; 69(5): 1527 - 1533.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Post and J. Waltenberger
Modulation of growth factor action in the cardiovascular system
Cardiovasc Res, February 15, 2005; 65(3): 547 - 549.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.